Pre-IPO BeiGene - Would the IPO on the STAR Market Be the Last Hurrah?
This article analyzed BeiGene in terms of its current pipeline, products on the market, competitive landscape, financial position, and the concerns...
280 Views
An Analysis of ADR/HKEX Discount Behavior As The US Listed Chinese Tech Rush To Hong Kong
As the US-listed Chinese tech firms rush for secondary listings on the Hong Kong Stock Exchange, we analyse the ADR/HKEX discount behaviour of the...
397 Views
BeiGene: Novartis Grabs Tislelizumab Rights
BeiGene's deal with Novartis for PD-1 tislelizumab validates its competitive position, and marks a rising trend of Chinese companies licensing...
274 Views
Ocumension Theraputics Placement - IPO Was Hot, Deal Should Be Supported Despite Lock-Up Expiry
Ocumension Therapeutics (1477 HK) aims to raise around US$103m to commercialize new products, fund clinical trials and develop new facilities.
285 Views
BeiGene: Cancer Treatment in China--The Underestimated Opportunity
We think that cancer is underdiagnosed and undertreated in China. We analyze the data and propose two approaches for investing in this theme.
339 Views